IMMUCELL CORP /DE/ shareholders approved To ratify the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2026. at the 2026-06-11 meeting.
“5. To ratify the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2026: For Against Abstain Broker Non-votes 7,344,196 14,645 38,854 0 99.28% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2026 was ratified.”
Shareholder Votes
IMMUCELL CORP /DE/ shareholders approved To approve an amendment to the Company’s Certificate of Incorporation to reflect certain Delaware law provisions regarding the exculpation of officers. at the 2026-06-11 meeting.
“4. To approve an amendment to the Company’s Certificate of Incorporation to reflect certain Delaware law provisions regarding the exculpation of officers: For Against Abstain Broker Non-votes 4,851,019 325,531 11,244 2,209,901 53.62% of total shares outstanding voted in favor. On the basis of this vote, the amendment to the Company’s Certificate of Incorporation to reflect certain Delaware law provisions regarding the exculpation of officers was approved.”
Shareholder Votes
IMMUCELL CORP /DE/ shareholders approved To approve the Company’s 2025 Stock Option and Incentive Plan. at the 2026-06-11 meeting.
“3. To approve the Company’s 2025 Stock Option and Incentive Plan: For Against Abstain Broker Non-votes 4,689,407 18,453 479,934 2,209,901 90.39% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the matter was approved.”
Shareholder Votes
IMMUCELL CORP /DE/ shareholders approved To approve a non-binding advisory resolution on the Company’s executive compensation program. at the 2026-06-11 meeting.
“2. To approve a non-binding advisory resolution on the Company’s executive compensation program: For Against Abstain Broker Non-votes 4,793,553 29,155 365,086 2,209,901 92.4% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the non-binding advisory resolution on the Company’s executive compensation program was approved.”
Shareholder Votes
IMMUCELL CORP /DE/ shareholders approved To elect to one-year terms as Directors of the Company the seven nominees listed in the 2026 Proxy Statement. at the 2026-06-11 meeting.
“1. To elect to one-year terms as Directors of the Company the nominees listed in the Company’s Proxy Statement dated April 24, 2026: For Withheld Broker Non-Votes Gloria J. Basse 5,177,979 9,815 2,209,901 P. Olivier te Boekhorst 5,180,197 7,597 2,209,901 Anthony A. Dimarco 5,179,503 8,291 2,209,901 Gilles Guillemette 5,166,860 20,934 2,209,901 David S. Tomsche 5,173,863 13,931 2,209,901 Kathy V. Turner 5,166,863 20,931 2,209,901 Paul R. Wainman 5,177,135 10,659 2,209,901 On the basis of this vote, each of the seven nominees was elected to a one-year term as a Director of the Company.”
Earnings Releases
IMMUCELL CORP /DE/ reported the quarter ended March 31, 2026 results: revenue approximately $10.4 million, net income $1.9 million, EPS $0.21 per basic share.
“million compared to the first quarter of 2025,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “These results were driven by 28.4% growth in product sales to $10.4 million and an expansion of gross margins to 45.0% that reflects higher volumes, manufacturing efficiencies, and price realization. ImmuCell generated $3.4 million free cash flow in the”
Material Agreements
IMMUCELL CORP /DE/ entered into Settlement Deed with Norbrook Laboratories Limited valued at $2,000,000 (effective 2026-05-08).
“On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.”
Earnings Releases
IMMUCELL CORP /DE/ reported the quarter ended March 31, 2026 results: revenue $10.4 million.
“health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026. Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. For the three-month period ended March 31: ● Domestic sales were $9.7 million in 2026, a 35.7% increase”
Earnings Releases
IMMUCELL CORP /DE/ reported financial results for year ended December 31, 2025.
“On March 4, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter and year ended December 31, 2025.”
Restructurings & Charges
IMMUCELL CORP /DE/ announced a impairment with charges of $0.6 million write-down affecting work-in-process colostrum inventory.
“a $0.6 million write-down primarily of work-in-process colostrum inventory that was determined to no longer be fit for processing into First Defense®”
Restructurings & Charges
IMMUCELL CORP /DE/ announced a impairment with charges of $0.1 million, non-cash impairment write-down affecting certain property, plant and equipment, unrelated to Re-Tain®.
“the Company has identified a $0.1 million, non-cash impairment write-down of certain property, plant and equipment”
Restructurings & Charges
IMMUCELL CORP /DE/ announced a impairment with charges of approximately $2.9 million affecting Re-Tain®.
“The resulting non-cash impairment write-down of property, plant and equipment pertaining to Re-Tain® is currently estimated at approximately $2.9 million”
Restructurings & Charges
IMMUCELL CORP /DE/ announced a impairment with charges of approximately $3.6 million in non-cash impairment write-downs affecting Re-Tain® assets and other property, plant and equipment and inventory.
“the Company announced that it will record approximately $3.6 million in non-cash impairment write-downs during the three-month period ended December 31, 2025.”
Restructurings & Charges
IMMUCELL CORP /DE/ announced a impairment with charges of approximately $2.3 million affecting production of Re-Tain ®.
“ImmuCell Corporation (“ImmuCell”) has announced strategy changes (see Item 8.01 below) that will result in a material charge for a non-cash impairment write-down of certain property, plant and equipment (primarily equipment) during the fourth quarter of 2025. The affected assets are ones relating to the production of Re-Tain ®. Some but not all of those assets will now be repurposed to manufacture First Defense ®. ImmuCell presently estimates the non-cash impact to profit to be approximately $2.3 million (subject to adjustment pursuant to review of alternate purposing and net realizable value to be completed as part of the financial closing for the quarter and year ending December 31, 2025).”
Debt Financings
IMMUCELL CORP /DE/ amended revolving credit of $1 million line of credit with Maine Community Bank (MCB) at variable at the National Prime Rate per annum maturing September 11, 2026.
“On August 20, 2025, ImmuCell Corporation (the “Company”) entered into an Allonge to and Amendment of Line of Credit (the “Allonge”) between the Company and Maine Community Bank (MCB) pursuant to which the Company’s $1 million line of credit with MCB was extended through September 11, 2026. Interest on borrowings against the Line of Credit is variable at the National Prime Rate per annum.”
Debt Financings
IMMUCELL CORP /DE/ incurred loan of $2,327,119 with Maine Community Bank at 6.5% per annum.
“On August 7, 2025, ImmuCell Corporation (the “Company”) entered into a Loan Agreement, Promissory Note, and other definitive agreements covering a loan transaction with Maine Community Bank (MCB). Proceeds from such loan transaction in the principal amount of $2,327,119, and bearing interest at a fixed rate of 6.5% per annum”
Timothy C. Fiori was elected as Chief Financial Officer at IMMUCELL CORP /DE/.
“The Board of Directors of ImmuCell Corporation (the Company) has elected Timothy C. Fiori, age 46, to serve as its Chief Financial Officer effective April 7, 2025.”
Earnings Releases
IMMUCELL CORP /DE/ reported the quarter ended March 31, 2024 results: revenue $7.3 million, net income Net loss was $438,000, EPS $0.06 per basic share.
“comparable period ended March 31, 2023. Total sales during the trailing twelve-month period ended March 31, 2024 were 33% above the comparable period ended March 31, 2023. The $7.3 million in sales recorded during the first quarter of 2024 represents an all-time quarterly sales record for the Company. The next highest quarter was $6 million recorded during the”
Material Agreements
IMMUCELL CORP /DE/ amended First Amendment to Economic Recovery Loan Program Loan Agreement with Finance Authority of Maine valued at amends the FAME Loan Agreement to remove any restrictions on the Company’s ability to issue equity s (effective 2024-04-08).
“In connection with entering into the Sales Agreement, on April 8, 2024, the Company entered into an amendment (the "First Amendment") to the Company's Economic Recovery Loan Program Loan Agreement, by and between the Company and the Finance Authority of Maine dated July 17, 2023 (the "FAME Loan Agreement").”
Material Agreements
IMMUCELL CORP /DE/ entered into At The Market Offering Agreement with Craig-Hallum Capital Group LLC valued at up to $11,000,000 of shares of common stock (effective 2024-04-09).
“On April 9, 2024, ImmuCell Corporation (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, up to $11,000,000 of shares of its common stock, par value $0.10 per share (the “Common Stock”).”
“first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Periods Ended March 31, $ 7.3 million $ 3.4 million $ 3.8 million 111 % During the Twelve-Month Periods Ended March 31, $ 21.3 million $ 16.0 million $ 5.3 million 33 % Total sales during the three-month period ended”
“On March 4, 2024, ImmuCell Corporation (the “Company”) entered into an Amending Agreement (the “Amendment”) with Norbrook Laboratories Limited (“Norbrook”), which Amendment amends that certain Development Services and Commercial Supply Agreement, dated September 5, 2019, by and between the Company and Norbrook (as amended to date, the “Agreement”).”
Debt Financings
IMMUCELL CORP /DE/ amended credit facility of $1 million with Gorham Savings Bank maturing through September 11, 2025.
“On February 22, 2024, ImmuCell Corporation (the “Company”) entered into an Allonge to and Amendment of Line of Credit (the “Allonge”) between the Company and Gorham Savings Bank (GSB) pursuant to which the Company’s $1 million line of credit with GSB was extended through September 11, 2025.”
Material Agreements
IMMUCELL CORP /DE/ amended Allonge to and Amendment of Line of Credit with Gorham Savings Bank valued at $1 million line of credit extended through September 11, 2025 (effective 2024-02-22).
“On February 22, 2024, ImmuCell Corporation (the “Company”) entered into an Allonge to and Amendment of Line of Credit (the “Allonge”) between the Company and Gorham Savings Bank (GSB) pursuant to which the Company’s $1 million line of credit with GSB was extended through September 11, 2025.”
Earnings Releases
IMMUCELL CORP /DE/ reported the year ended December 31, 2023 results: revenue $17.5 million, net income Net loss was $5.8 million, EPS $0.75 per basic share.
“Product sales decreased by 6%, or $1.1 million, to $17.5 million during the year ended December 31, 2023 compared to $18.6 million during the year ended December 31, 2022.”
Earnings Releases
IMMUCELL CORP /DE/ reported the three-month period ended December 31, 2023 results: revenue $5.1 million, net income Net loss was $1.1 million, EPS $0.15 per basic share.
“Product sales increased by 30%, or $1.2 million, to $5.1 million during the three-month period ended December 31, 2023 compared to $3.9 million during the three-month period ended December 31, 2022.”
Earnings Releases
IMMUCELL CORP /DE/ reported financial results for the quarter and year ended December 31, 2023.
“On February 27, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter and year ended December 31, 2023.”
Earnings Releases
IMMUCELL CORP /DE/ reported preliminary financial results for the year ended December 31, 2023.
“On January 8, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited product sales for the year ended December 31, 2023.”
Earnings Releases
IMMUCELL CORP /DE/ reported preliminary financial results for the fourth quarter of 2023, which ended December 31, 2023.
“On January 8, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited product sales for the year ended December 31, 2023.”
Material Agreements
IMMUCELL CORP /DE/ amended Third Amendment of Lease with TVP, LLC (the Landlord) valued at additional monthly rent payments of $20,000 through June 2024 and a one-time rent payment of $488,74 (effective 2023-11-14).
“On November 14, 2023, ImmuCell Corporation (the “Company”) entered a Third Amendment of Lease (the “Lease Amendment”), which Lease Amendment amends that certain Indenture of Lease, dated September 12, 2019 (the “Lease Agreement”), by and between the Company and TVP, LLC (the “Landlord”)”
Earnings Releases
IMMUCELL CORP /DE/ reported the quarter ended September 30, 2023 results: revenue $5.4 million, net income Net loss was $940,000, or $0.12 per basic share, EPS $0.12 per basic share.
“to traditional antibiotics that is subject to FDA approval,” concluded Mr. Brigham. 1 of 6 Certain Financial Results: ● Product sales increased by 13%, or $600,000, to $5.4 million during the three-month period ended September 30, 2023 compared to $4.8 million during the three-month period ended September 30, 2022. ● Product sales decreased by 16%, or $2.3”
“September 30, 2023. Preliminary, Unaudited Total Sales Results: 2023 2022 $ Increase ($ Decrease) % Increase (% Decrease) During the Three-Month Periods Ended September 30, $ 5.40 million $ 4.80 million $ 600,000 13 % During the Nine-Month Periods Ended September 30, $ 12.38 million $ 14.66 million $ (2.28 million ) (16 %) During the Trailing Twelve-Month Periods”
Earnings Releases
IMMUCELL CORP /DE/ reported the trailing twelve-month period ended June 30, 2023 results: revenue $15.7 million.
“Product sales decreased by 23%, or $4.8 million, to $15.7 million during the trailing twelve-month period ended June 30, 2023 compared to $20.5 million during the trailing twelve-month period ended June 30, 2022.”
Earnings Releases
IMMUCELL CORP /DE/ reported the six-month period ended June 30, 2023 results: revenue $7.0 million, net income ($3.7) million, EPS ($0.48) per basic share.
“the three-month period ended June 30, 2023 compared to $3.9 million during the three-month period ended June 30, 2022. ● Product sales decreased by 29%, or $2.9 million, to $7.0 million during the six-month period ended June 30, 2023 compared to $9.9 million during the six-month period ended June 30, 2022. ● Product sales decreased by 23%, or $4.8 million, to”
Earnings Releases
IMMUCELL CORP /DE/ reported the quarter ended June 30, 2023 results: revenue $3.5 million, net income ($1.4) million, EPS ($0.18) per basic share.
“review shortly, which is a critical milestone in our efforts to commercialize this product.” 1 of 6 Certain Financial Results: ● Product sales decreased by 9%, or $329,000, to $3.5 million during the three-month period ended June 30, 2023 compared to $3.9 million during the three-month period ended June 30, 2022. ● Product sales decreased by 29%, or $2.9 million,”
Debt Financings
IMMUCELL CORP /DE/ incurred term loan of $1 million with Finance Authority of Maine at fixed rate of 8.00% per annum maturing three-year term.
“The FAME facility is a $1 million term note bearing interest at a fixed rate of 8.00% per annum with monthly principal and interest payments based on a seven-year amortization schedule with a three-year term.”
Debt Financings
IMMUCELL CORP /DE/ incurred term loan of $2 million with Gorham Savings Bank at fixed rate of 7.00% per annum maturing three-year term.
“The GSB facility is a $2 million term note bearing interest at a fixed rate of 7.00% per annum with monthly principal and interest payments based on a seven-year amortization schedule with a three-year term.”
Shareholder Votes
IMMUCELL CORP /DE/ shareholders approved To ratify the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2023. at the 2023-06-15 meeting.
“4. To ratify the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2023: For Against Abstain Broker Non-votes 5,687,633 9,343 8,569 0”
Shareholder Votes
IMMUCELL CORP /DE/ shareholders rejected To approve a non-binding advisory vote on whether to amend the Company’s Common Stock Rights Plan extending its expiration date by one year to September 19, 2024. at the 2023-06-15 meeting.
“3. To approve a non-binding advisory vote on whether to amend the Company’s Common Stock Rights Plan extending its expiration by one year to September 19, 2024: For Against Abstain Broker Non-votes 2,390,931 1,270,796 10,930 2,032,888”
Shareholder Votes
IMMUCELL CORP /DE/ shareholders approved To approve a non-binding advisory resolution on the Company’s executive compensation program. at the 2023-06-15 meeting.
“2. To approve a non-binding advisory resolution on the Company’s executive compensation program: For Against Abstain Broker Non-votes 3,293,046 76,241 303,370 2,032,888”
Shareholder Votes
IMMUCELL CORP /DE/ shareholders approved To elect to one-year terms as Directors of the Company the six nominees listed in the 2023 Proxy Statement. at the 2023-06-15 meeting.
“1. To elect to one-year terms as Directors of the Company the nominees listed in the Company’s Proxy Statement dated April 28, 2023: For Withheld Broker Non-votes Gloria J. Basse 3,594,248 78,409 2,032,888 Michael F. Brigham 3,590,547 82,110 2,032,888 Bobbi Jo Brockmann 3,614,602 58,055 2,032,888 Steven T. Rosgen 3,592,944 79,713 2,032,888 David S. Tomsche 3,555,331 117,326 2,032,888 Paul R. Wainman 3,547,166 125,491 2,032,888”
Bryan K. Gathagan was elected as independent director at IMMUCELL CORP /DE/.
“Pursuant to a recommendation by the Nominating Committee, the board of directors (the “Board”) of ImmuCell Corporation (the “Company”) elected Mr. Bryan K. Gathagan as an independent director, effective June 16, 2023.”
Earnings Releases
IMMUCELL CORP /DE/ reported the quarter ended March 31, 2023 results: revenue $3.4 million, net income ($2.3) million, EPS ($0.30) per basic share.
“Product sales decreased by 43%, or $2.6 million, to $3.4 million during the three-month period ended March 31, 2023”
Earnings Releases
IMMUCELL CORP /DE/ reported the first quarter of 2023, which ended March 31, 2023 results: revenue $3.45 million.
“unaudited sales results for the first quarter of 2023, which ended March 31, 2023. 2023 2022 ($ Decrease) (% Decrease) During the Three-Month Periods Ended March 31, $3.45 million $6.00 million ($2.55 million) (43 )% During the Twelve-Month Periods Ended March 31, $16.01 million $21.14 million ($5.12 million) (24 )% Actual sales during the first quarter of”
Earnings Releases
IMMUCELL CORP /DE/ reported financial results for the year ended December 31, 2022.
“On February 21, 2023 ImmuCell Corporation (the "Company") issued a press release announcing the unaudited financial results for the year ended December 31, 2022.”
David S. Cunningham departed as Director at IMMUCELL CORP /DE/.
“On January 24, 2023, David S. Cunningham notified ImmuCell Corporation (the “Company”) of his intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2023 Annual Meeting to be held on June 15, 2023.”
Earnings Releases
IMMUCELL CORP /DE/ reported for the year ended December 31, 2022 results: revenue $18.57 million.
“(% Decrease) During the Three-Month Periods Ended December 31, $ 3.91 million $ 5.44 million $ (1.53 million) (28.2 )% During the Twelve-Month Periods Ended December 31, $ 18.57 million $ 19.24 million $ (675,000 ) (3.5 )% As of December 31, 2022, there was a backlog of orders equal to approximately $2.5 million, representing an increase from”
Earnings Releases
IMMUCELL CORP /DE/ reported the nine-month periods ended September 30, 2022 results: revenue $ 14.66 million, net income ($826,000), EPS ($0.11) per basic share.
“(% Decrease ) % Increase During the Three-Month Periods Ended September 30, $ 4.80 million $ 5.15 million $ (354,000 ) (7 )% During the Nine-Month Periods Ended September 30, $ 14.66 million $ 13.80 million $ 858,000 6 % During the Twelve-Month Periods Ended September 30, $ 20.10 million $ 17.54 million $ 2.56 million 15 % Management’s Discussion: “As we work our way”
Earnings Releases
IMMUCELL CORP /DE/ reported the quarter ended September 30, 2022 results: revenue $ 4.80 million, net income ($655,000), EPS ($0.08) per basic share.
“quarter ended September 30, 2022. Unaudited Total Sales Results: 2022 2021 ($ Decrease ) $ Increase (% Decrease ) % Increase During the Three-Month Periods Ended September 30, $ 4.80 million $ 5.15 million $ (354,000 ) (7 )% During the Nine-Month Periods Ended September 30, $ 14.66 million $ 13.80 million $ 858,000 6 % During the Twelve-Month Periods Ended September”
Auditor Changes
IMMUCELL CORP /DE/ reported that prior financial statements should not be relied upon.
“such Previously Issued Financial Statements should no longer be relied upon to that extent.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.